readthroughSign in
CompanyIKTNasdaqWilmington, DE

Inhibikase Therapeutics

Inhibikase Therapeutics develops IKT-001, a prodrug of imatinib for pulmonary arterial hypertension (PAH), an orphan indication.

10-QNov 16Latest SEC filing
Nov 10Latest story